Atara Biotherapeutics (ATRA) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRA shares.
View ATRA analyst ratings or view top-rated stocks.

3 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their ATRA share price forecasts range from $25.00 to $31.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 1,730.1% from the stock's current price.
View analysts price targets for ATRA or view top-rated stocks among Wall Street analysts.

Atara Biotherapeutics' stock was trading at $3.28 on January 1st, 2023. Since then, ATRA shares have decreased by 53.4% and is now trading at $1.53.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ATRA earnings forecast.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) posted its earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.03. The biotechnology company had revenue of $0.96 million for the quarter, compared to analyst estimates of $3.36 million. Atara Biotherapeutics had a negative net margin of 4,437.45% and a negative trailing twelve-month return on equity of 315.45%.

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Atara Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baupost Group LLC MA (9.67%), Wasatch Advisors LP (8.46%), BlackRock Inc. (8.17%), JPMorgan Chase & Co. (7.64%), Goldman Sachs Group Inc. (4.51%) and State Street Corp (2.51%). Insiders that own company stock include Amar Murugan, Eric J Hyllengren, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends.

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRA stock can currently be purchased for approximately $1.53.

Atara Biotherapeutics (NASDAQ:ATRA) has a market capitalization of $154.68 million and generates $63.57 million in revenue each year. The biotechnology company earns $-228,300,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis.

The company employs 317 workers across the globe.

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.atarabio.com. The biotechnology company can be reached via phone at (805) 623-4211 or via email at ehyllengren@atarabio.com.